The US FDA Drug Establishments Current Registration Site is an official public database that allows users to verify drug manufacturing facilities registered with the U.S. Food and Drug Administration (FDA). This system plays a central role in ensuring transparency across the pharmaceutical supply chain by displaying establishments that have completed FDA drug establishment registration.
For manufacturers, importers, distributors, and compliance teams, this site is an essential resource for confirming whether a facility holds an active registration status.
What Is the FDA Drug Establishments Current Registration Site?
The FDA Drug Establishments Current Registration Site is part of the FDA’s registration and listing infrastructure. It contains records of:
- Domestic drug manufacturing establishments
- Foreign drug establishments exporting to the US
- Facility name and address
- Registration status
Only establishments that have submitted registration and completed required annual renewals appear as active in the database.
It is important to understand that registration does not mean FDA approval. Registration simply confirms that the facility has fulfilled its administrative notification obligation.
Why the FDA Maintains This Database
The FDA uses the current registration site to maintain oversight of facilities involved in drug manufacturing and processing. The database helps the FDA to:
- Identify where drugs are manufactured or handled
- Determine which facilities are subject to FDA inspection
- Support import screening and compliance verification
- Assist in recalls and safety investigations
For industry users, the database supports due diligence before selecting manufacturing partners or suppliers.
Who Is Listed on the Registration Site?
The site includes establishments such as:
- Prescription drug manufacturers
- Over-the-counter (OTC) drug manufacturers
- Contract manufacturing organizations (CMOs)
- Repackers and relabelers
- Foreign drug manufacturers supplying the US
All these facilities must renew their registration annually to remain visible as active.
How to Search the FDA Registration Site
Users can search the database using:
- Establishment name
- Company name
- Address or country
- Registration number
Search results display basic facility information and registration status, allowing quick verification.
Because registration status can change after annual renewal, regular verification is recommended.
Annual Registration and Data Accuracy
FDA drug establishment registration must be renewed each year between October 1 and December 31. Facilities that fail to renew may appear as inactive or may not display in current search results.
Maintaining accurate registration data ensures continued visibility in the database and reduces the risk of shipment delays or compliance findings.
Common Misunderstandings
Some frequent misconceptions include:
- Thinking database listing equals FDA approval
- Believing registration is permanent
- Assuming products made at a registered facility are automatically FDA-approved
In reality, registration is a recurring administrative requirement only.
Why Professional FDA Registration Support Matters
Correct appearance in the FDA registration site requires accurate initial registration, timely annual renewal, and proper data maintenance. Even small errors can lead to inactive status or regulatory delays.
XPRO America, a US FDA Consultancy, provides comprehensive FDA drug establishment registration services, including new registrations, annual renewals, data verification, and US Agent support for foreign companies.
Organizations seeking reliable FDA registration assistance can contact support@xproamerica.com for professional guidance.
Conclusion
The US FDA Drug Establishments Current Registration Site is a vital tool for verifying registered drug manufacturing facilities. However, maintaining correct and active registration requires ongoing attention.
By ensuring proper FDA establishment registration—and partnering with an experienced US FDA Consultancy—companies can minimize compliance risks, avoid supply chain disruptions, and maintain uninterrupted access to the US pharmaceutical market.
Leave a Reply